AKEOS (09926)5 drugs that have been marketed have all successfully been included in the latest version of the national medical insurance drug list.

AKESO (09926) announced that five new drugs from AKESO have been listed, including Kantani (cadinilum, PD-1/CTLA-4), Ida Fang (ivose, PD-1/VEGF), Anniclo (paanpreli, PD-1), Ixin (inusi, PCSK9) and Aidaro (yiroqi, IL-12 / IL-23), and all approved indications have been successfully included in the latest version of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2025)" ("National Medical Insurance Drug List" or "List") published by the National Medical Insurance Bureau of China. The 2025 edition of the National Medical Insurance Drug List will officially take effect on January 1, 2026. Kantani (Cadinil, PD-1/CTLA-4) has successfully renewed the indications for recurrent or metastatic cervical cancer in the original list, and added indications for first-line treatment of locally advanced unresectable or metastatic stomach or gastroesophageal junction, as well as first-line treatment for continuous, recurrent or metastatic cervical cancer included in the 2025 version list. Ida Fang (ivose, PD-1/VEGF) has successfully renewed the indications after progression with EGFR-TKI for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in the original list, and added indications for first-line treatment of PD-L1 positive (TPS1%) locally advanced or metastatic NSCLC included in the 2025 version list. Anniclo (paanpreli, PD-1), developed jointly by our company and SINO BIOPHARM Limited (stock code: 1177.HK) and its subsidiaries, has been included in the 2025 version list for the treatment of second-line and above classical Hodgkin's lymphoma, first-line locally advanced or metastatic squamous NSCLC, second-line or above nasopharyngeal cancer, as well as first-line nasopharyngeal cancer. Ixin (inusi, PCSK9) has been included in the 2025 version list for the treatment of primary hypercholesterolemia and mixed hyperlipidemia, and heterozygous familial hypercholesterolemia. Aidaro (yiroqi, IL-12/IL-23) has been included in the 2025 version list for the treatment of moderate to severe plaque psoriasis. The company is committed to bringing more global firsts and best treatment options for patients, and continuously improving the accessibility and affordability for patients. The company will deepen its efforts in major disease areas, promote more innovative drugs and new indications to be included in the national medical insurance drug list, benefiting more patients.